IN the loop

Clinical trials using biomarkers and why randomised control studies are unethical in rare

By Emma Bishop, RARE Revolution

13 October 2025

IN the loop

The power of words: How should we write about science?

By Florence Cornish, life sciences writer

29 September 2025

IN the loop

Looking ahead: the future for rare disease research and treatment

By Julie Penfold, RARE Revolution

22 September 2025

IN the loop

Progress in delivering rare therapies

By Julie Penfold, RARE Revolution

15 September 2025

IN the loop

A global vision for rare disease: Inside the ground-breaking RDI-Lancet Commission on Rare Diseases

By Emma Bishop, RARE Revolution

8 September 2025

IN the loop

Four years of the UK’s Rare Diseases Framework – what progress has been made?

By Julie Penfold, RARE Revolution

1 September 2025

IN the loop

The trust–success ratio: Why building trust is the cornerstone of PPIE (Public Patient Participation Inclusive and Engagement) – A patient’s perspective

By CONTRIBUTOR

25 August 2025

IN the loop

Breaking the cycle: rebuilding trust in medical research and delivery

By Nicola Miller, RARE Revolution

18 August 2025

IN the loop

Understanding the true cost of clinical trials

By CONTRIBUTOR

4 August 2025

IN the loop

Stretched thin

By Nicola Miller, RARE Revolution

28 July 2025

IN the loop

Health and humanity – why holistic care must be a shared industry responsibility

By CONTRIBUTOR

7 July 2025